Hoffman-La Roche has a new trial they have initiated for Polycythemia Vera, for those who are either resistant to or intolerant of Hydroxyurea. The drug – NP39761 or Idasanutlin – is being tested in a Phase 1, single arm trial. The drug is taken orally by patients, and disrupts certain cancer causing pathways relevant to the JAK2 mutation. Outcomes for this trial vary based on the patient criteria going in, such as spleen size, hematocrit level and other variables. More information about this tria, including expected outcomes, is available on ClinicalTrials.gov by clicking here. Genentech Roche also has an information page about this trial available here.
NEW DRUG TRIAL FOR POLYCYTHEMIA VERA INITIATED
admin | April 28, 2021